| Literature DB >> 34652518 |
Matilda Naesström1, Johannes Johansson2, Marwan Hariz3,4, Owe Bodlund5, Karin Wårdell2, Patric Blomstedt3.
Abstract
BACKGROUND: Deep brain stimulation (DBS) is being investigated as a treatment for therapy-refractory obsessive compulsive disorder (OCD). Many different brain targets are being trialled. Several of these targets such as the ventral striatum (including the nucleus accumbens (NAc)), the ventral capsule, the inferior thalamic peduncle, and the bed nucleus of stria terminalis (BNST)) belong to the same network, are anatomically very close to one another, or even overlap. Data is still missing on how various stimulation parameters in a given target will affect surrounding anatomical areas and impact the clinical outcome of DBS.Entities:
Keywords: Bed nucleus of stria terminalis (BNST); Deep brain stimulation (DBS); Electric field; Obsessive compulsive disorder (OCD); Simulation
Mesh:
Year: 2021 PMID: 34652518 PMCID: PMC8761125 DOI: 10.1007/s00701-021-04991-0
Source DB: PubMed Journal: Acta Neurochir (Wien) ISSN: 0001-6268 Impact factor: 2.816
Fig. 1The encircled areas show individual electric fields at 12 months’ follow-up in each of the 11 patients
Fig. 2Finite element method model of two Medtronics 3387 leads visualized along the plane of the electrodes. The deepest contact lies 3 mm below the AC-PC plane
Stimulation settings and % improvement in Y-BOCS at 12 and 24 months follow up
| 12 months | 24 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no | Electrode | Contacts | Volt | Pulse width (msec) | Frequency (Hz) | Y-BOCS | Contacts | Volt | Pulse width (msec) | Frequency (Hz) | Y-BOCS improvement |
| 1 | 3387 | Left: − 0, − 1 Right: − 10, − 11 | 3.2 | 90 | 130 | 53% | Left: − 0, − 1 Right: − 9,10 − 11 | 5.2/ 4.5 | 90 | 130 | 40% |
| 2 | 3389 | Left: − 2 Right: − 9 | 3.5 | 60 | 130 | 56% | Left: + 0, − 1 − 2, + 3 Right: − 8, − 9 + 10 | 3.5 | 150 | 130 | 66% |
| 3 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 5 | 120 | 130 | 60% | Left: − 1, − 2 Right: − 9, − 10 | 4.4 | 120 | 130 | 49% |
| 4 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 4.2 | 150 | 130 | 10% | Left: − 1, − 2 Right: − 9, − 10 | 4.2 | 120 | 130 | 38% |
| 5 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 4.1 | 90 | 130 | 45% | Left: − 1, − 2 Right: − 9, − 10 | 5 | 90 | 130 | 42% |
| 6 | 3389 | Left: − 0, − 1 − 2, Right: − 9 − 10, − 11 | 4 | 60 | 130 | 47% | Left: − 0, − 1 − 2, Right: − 9 − 10, − 11 | 4 | 60 | 130 | 13% |
| 7 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 4.9 | 90 | 130 | 34% | Left: − 1, − 2 Right: − 9, − 10 | 5.1 | 90 | 130 | 34% |
| 8 | 3387 | Left: − 1, − 2 | 3.8 | 60 | 130 | 25% | Left: − 1, − 2 | 3.8 | 60 | 130 | 34% |
| 9 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 4.4 | 60 | 130 | 41% | Left: − 1, − 2 Right: − 9, − 10 | 4.4 | 60 | 130 | 65% |
| 10 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 4.3 | 90 | 130 | 25% | Left: − 1, − 2 Right: − 9, − 10 | 3.9 | 90 | 130 | 22% |
| 11 | 3387 | Left: − 1, − 2 Right: − 9, − 10 | 3.5 | 90 | 130 | 36% | Left: − 1, − 2 Right: − 9, − 10 | 3.5 | 90 | 130 | 33% |
Fig. 3Group simulation fields at 12 months’ follow-up
Fig. 4Anatomical target overview